← All trials
NCT03056391
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2016
- Primary completion
- Aug 1, 2018
- Completion date
- Aug 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Menzies School of Health ResearchLead sponsor
- Menzies School of Health ResearchStudy director
- Jesselton Medical CentreStudy director
- Mahidol UniversityStudy director
- Queen Elizabeth Hospital, Kota Kinabalu, Sabah, MalaysiaOverall official - principal investigator
- Government of MalaysiaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.